Navigating the complex world of pharmaceuticals can be daunting. India, a global giant in the pharma industry, is home to numerous leading companies that dominate this sector. You might be intrigued to discover who’s at the top and what they’re doing differently.
India’s top 10 pharmaceutical companies have something in common – their relentless pursuit of innovation and commitment to improving healthcare across the globe. These companies strike a balance between cutting-edge research, affordability, and accessibility.
From established giants like Sun Pharma and Lupin, to emerging players making waves in biotechnology, these firms are shaping India’s medical landscape while having a significant impact on global health solutions. Let’s delve into their achievements, strategies, and how they’ve managed to rise above the rest.
For further insights into healthcare and related sectors, you can explore the leading water treatment companies in India.
Pharma Industry in India
- The total market size of the Indian Pharma Industry is expected to reach US$ 130 billion by 2030.
- The Ministry’s scheme “Strengthening of Pharmaceutical Industry (SPI)” with a total financial outlay of US$ 60.9 million extends support required to existing pharma clusters and MSMEs across the country to improve their productivity, quality and sustainability.
- The Government has set a target to increase the number of Pradhan Mantri Bhartiya Jan Aushadhi Kendras (PMBJKs) to 10,500 by the end of March 2025.
- The cumulative FDI equity inflow in the Drugs and Pharmaceuticals industry is US$ 21.22 billion during the period April 2000-December 2022.
- Indian pharma companies have a substantial share in the prescription market in the US and EU. The largest number of FDA-approved plants outside the US is in India.
- India is the largest producer of generic drugs in the world.
- India’s domestic pharmaceutical industry’s annual turnover reached over 42 billion U.S. dollars in 2021.
- India manufactures about 60,000 different generic brands across 60 therapeutic categories and accounts for 20% of the global supply of generics.
- The pharmaceutical industry in India is expected to reach $65 Bn by 2024 and to $130 Bn by 2030.
Alongside pharmaceuticals, India is also progressing in other sectors. Discover the electric vehicle manufacturing companies in India leading this change.
Besides pharmaceuticals, the specialty chemical sector is also growing. Explore the specialty chemical companies in India.
Pharma Companies in India
- Sun Pharmaceutical Industries Ltd
- Dr. Reddy’s Laboratories Ltd
- Cipla Ltd
- Divis Laboratories Ltd
- Aurobindo Pharma
- Mankind Pharma Ltd
- Torrent Pharmaceuticals Ltd
- Zydus Lifesciences Ltd
- Biocon Ltd
- Lupin Ltd.
| Company | Revenue (INR Crore) |
|---|---|
| Sun Pharmaceutical Industries Ltd | 395,000 |
| Dr. Reddy’s Laboratories Ltd | 17,553 |
| Cipla Ltd | 12,827 |
| Divis Laboratories Ltd | 9,073 |
| Aurobindo Pharma Ltd | 248,000 |
| Mankind Pharma Ltd | 8,127 |
| Torrent Pharmaceuticals Ltd | 8,500 |
| Biocon Ltd | 11,550 |
| Lupin Ltd | 11,350 |
- Sun Pharmaceutical Industries Ltd: Revenue – INR 395,000 Crore
- Dr. Reddy’s Laboratories Ltd: Revenue – INR 17,553.80 Crore
- Cipla Ltd: Revenue – INR 12,827.29 Crore
- Divis Laboratories Ltd: Revenue – INR 9,073 Crore
- Aurobindo Pharma Ltd: Revenue – INR 248,000 Crore
- Mankind Pharma Ltd: Revenue – INR 8,127.15 Crore
- Torrent Pharmaceuticals Ltd: Revenue – INR 8,500 Crore
- Biocon Ltd: Revenue – INR 11,550 Crore
- Lupin Ltd: Revenue – INR 11,350.09 Crore
1. Sun Pharmaceutical Industries Ltd
Standing tall as India’s largest pharmaceutical company, Sun Pharmaceutical Industries Ltd, fondly known as Sun Pharma, has also made its mark internationally. It proudly ranks as the fourth-largest specialty generics pharmaceutical company worldwide. With its headquarters in Mumbai, Maharashtra, this multinational firm is a significant player on the global stage.
Sun Pharma had an impressive consolidated income of over 395 billion Indian rupees (equivalent to 3,95,000 crores) during the fiscal year of 2022. However, it wasn’t all smooth sailing. The last quarter showed a net loss of INR 2,277 crore due to one-off exceptional losses totalling INR 3,936 crore.
In terms of manpower strength in 2021, Sun Pharma employed more than 37,000 individuals globally.
Sun Pharma’s extensive range includes generic formulations along with branded generics and speciality products. They’re particularly renowned for their complex technology-intensive products that are often challenging to make. Over-the-counter drugs (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and intermediates also form part of their portfolio. Their broad spectrum caters to treating psychiatric disorders neurological conditions nephrological diseases gastroenterological issues orthopedic ailments ophthalmologic problems and heart diseases among others.
Healthcare professionals and patients from over a hundred countries around the world count themselves among Sun Pharma’s clientele.
From small beginnings in 1983 to being one amongst the top ten generic pharma companies in America today – that’s Sun Pharma’s journey so far! It even holds second place for prescriptions within the American generic dermatology market.
In recent years like 2023 saw some strategic acquisitions by Sun Pharma which included taking a 60% stake in the animal healthcare company, Vivaldis Animal Health and Foods Pvt Ltd. Other acquisitions in that year included a 38% stake in EzeRx Health Tech Private Ltd. and a 4.04% stake in Agasta Software.
Founded back in 1983 and listed on the stock market by ’94, Sun Pharma’s growth has been an interesting mix of organic expansion and strategic acquisitions. Included among its significant purchases are Tamil Nadu Dadha Pharmaceuticals Limited (TDPL), Milmet Labs, Gujarat Lyka Organics and Taro Pharmaceuticals.
Sun Pharma holds the title for being India’s largest pharmaceutical company while also featuring amongst America’s top ten generic pharma companies. In terms of prescriptions within the American generic dermatology market, it holds second place.
Sun Pharma’s major strength lies in their knack for developing generics as well as technologically complex products with over 2,700 employees dedicated to R&D.
Over time, Sun Pharma has made numerous acquisitions including buying up stakes like – a substantial 60% in Vivaldis Animal Health and Foods Pvt Ltd., a decent portion amounting to 38% in EzeRx Health Tech Private Ltd.,and somewhat smaller share of about 4.04% in Agasta Software during the year of 2023.
In addition to pharmaceuticals, there’s a diverse market in consumer goods. To learn more, check out consumer durable companies in India.
2. Dr. Reddy’s Laboratories Ltd
Standing tall in the league of pharmaceutical giants, Dr. Reddy’s Laboratories Ltd has made a name for itself on the international stage. Founded by the visionary scientist and entrepreneur Dr. K Anji Reddy, this company has consistently strived to provide affordable and innovative medicines to all corners of the globe.
In terms of financial performance, Dr. Reddy’s recorded an impressive total revenue of INR 17,553.80 crores in 2022 fiscal year with a net profit after tax amounting to INR 2,612.80 crores.
The company has seen continuous growth in its workforce as well, employing a total of 24,795 individuals as of 2022 which marked an increase by 9.04% from the previous year.
Dr. Reddy’s offers a wide range of pharmaceutical products covering therapy areas such as Gastrointestinal, Oncology, Pain Management among others including:
- Sapropterin Dihydrochloride
- DOXOrubicin HCI Liposome
- Bivalirudin
- Sumatriptan Injection
- Fingolimod Capsules
Their reach is global having operations across USA, India, Russia & CIS countries and Europe.
Their headquarters are located at Banjara Hills in Hyderabad reflecting their strong Indian roots but they’re not limited by geography with research and development centres located globally such as in Princeton (USA) and Bachupally Village (India).
Dr.Reddy’s commitment towards sustainability and gender equality is praiseworthy too! It was included in S&P Global’s Sustainability Yearbook for two consecutive years and Bloomberg Gender Equality Index for five straight years till 2022. It also bagged ‘Sustainable Corporate of the Year’ award at Frost & Sullivan-TERI Sustainability Awards.
In addition to these accolades, it was also the second runner-up in UN Women’s Empowerment Principles (WEPs) Gender Inclusive Workplace category in Asia-Pacific and one of India’s top companies for sustainability at Economic Times SDG Summit.
Its founder Dr K Anji Reddy is a figure who commands immense respect and recognition within the industry.
The logistics sector is also integral to pharma. Find more information on logistics companies in India.
3. Cipla Ltd
Diving straight into the figures, there’s something impressive to note about Cipla Ltd. For the fiscal year 2022, this titan of the pharma industry reported net sales/income from operations totalling a whopping ₹12,827.29 crores. With a net profit standing at an impressive ₹2,957.93 crores, it’s clear that this company is one strong player in India’s pharmaceutical sector.
Back in 2018 they boasted over 22,036 employees worldwide.
Cipla primarily develops medicines designed to combat a variety of medical conditions including respiratory disease and cardiovascular disease – not to mention arthritis, diabetes and depression too! They also sell active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products is also part of their remit.
When we talk about key clients for Cipla we’re looking at healthcare professionals and patients across many different countries –86 to be precise! Their reach is truly global with offices right around the world including their headquarters located at Cipla House in Mumbai.
Let’s take a moment now to celebrate some major achievements from this powerhouse pharma company: Notably becoming the world’s largest manufacturer of antiretroviral drugs and boasting an impressive footprint with 47 manufacturing locations globally!
In terms of notable projects or partnerships within recent years there’s definitely one worth mentioning: Back in 2019 Cipla entered digital therapeutics by partnering up with Wellthy Therapeutics in India and Brandmed in South Africa.
Casting our minds back to where it all began; Cipla was founded way back in 1935 by Khwaja Abdul Hamied under its original name, the Chemical, Industrial & Pharmaceutical Laboratories in Mumbai. Fast forward to 1984 and the name of the company was changed to ‘Cipla Limited’.
As we move into 2022, it’s interesting to note that the promoter group Y.K. Hamied and his family hold around a 33.61% equity share in Cipla. Individual shareholders also hold a noteworthy chunk of its shares at approximately 14.72%.
During FY 2013–14 they spent ₹517 crore (5.4% of their revenue) on R&D activities with the primary focus being on developing new formulations, drug-delivery systems and APIs.
Lastly let’s touch upon subsidiaries and acquisitions: In September 2015 Cipla acquired both InvaGen Pharmaceuticals and Exelan Pharmaceuticals – two American pharmaceutical companies for a tidy sum of $555 million dollars.
And let’s not forget its founder Khwaja Abdul Hamied who remains an iconic figure within the pharmaceutical industry.
4. Divis Laboratories Ltd
Divis Laboratories Ltd, India’s fourth-largest publicly-listed pharmaceutical company, has made its mark in the pharma industry by specialising in manufacturing Generic APIs and Nutraceutical Ingredients. It also offers custom synthesis of APIs to Big Pharma, a strategic move that provides them with a competitive edge over the entire life cycle of their products.
The company’s financial performance has been robust. For instance, in the fiscal year 2022, they reported an impressive revenue of ₹9,073 crores (approximately $1.1 billion), with a net profit amounting to ₹3,683 crores (about $460 million). However, it wasn’t all smooth sailing for this pharma giant as they experienced a 49% year-on-year fall in consolidated net profit at ₹356 crores during Q1 of 2023.
As for their workforce? Well, as of 2022, Divis Labs boasts roughly 17k employees who work tirelessly towards achieving the firm’s objectives. Their headquarters can be found amidst the hustle-bustle of Hyderabad city – nestled within Divi Towers located at Cyber Hills.
Their key clients are some big names from the multinational pharmaceutical industry – six out of ten largest ones to be precise! This is hardly surprising given their dominance in certain segments. The firm holds between a whopping 60-85% global market share in generic naproxen, dextromethorphan and gabapentin APIs while maintaining a respectable presence (20-30%) when it comes to pregabalin and methylamine APIs.
With its roots dating back to 1990 when it was established as Divi’s Research Centre initially developing commercial processes for API production and intermediates’ manufacturing; this organisation has come far indeed! They signalled their intent to enter into API and intermediates manufacturing industry by changing their name from Divi’s Research Centre to Divi’s Laboratories Limited in 1994.
Their research and development (R&D) team is heavily engaged in creating non-infringing processes that are commercially viable throughout the product’s lifecycle. They also focus on implementing continuous process improvements, thereby ensuring they stay competitive within the industry.
In terms of subsidiaries and acquisitions, Divis Labs has quite a few under their belt including Divis Laboratories (USA) Inc, Divi’s Laboratories Europe AG, and Divi’s Nutraceuticals. Their key people include Murali Krishna Prasad Divi and Satchandra Kiran Divi.
To sum up this section about Divis Labs: it’s a company that not only excels at what it does but is also committed to constant innovation and improvement – essential qualities for any organisation hoping to make an impact in today’s fast-paced pharma world.
5. Aurobindo Pharma
When it comes to revenue and profit, Aurobindo Pharma Limited has shown impressive figures. In the fiscal year 2023, they generated a staggering revenue of over 248 billion Indian rupees. Their consolidated net profit jumped by 10% to Rs 571 crore in the first quarter ending June 30, 2023.
As of the close of 2020, around 23,000 individuals worldwide benefited from employment opportunities at Aurobindo Pharma.
Their product range is equally robust. Known as a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, Aurobindo has its fingers in many pies – Antibiotics, AntiRetrovirals, Anti-Allergies, Anti-Diabetics and other therapeutic areas.
The company’s reach extends far beyond India’s borders with exports to over 150 countries across the globe. More than 90% of its revenues are derived from international operations. And they’ve got some heavy-hitters on their client list including names like AstraZeneca and Pfizer.
Aurobindo’s journey towards sustainability is well-documented in its sustainability report where you’ll find notable achievements showcasing their commitment to creating a healthier ecosystem.
They’ve made headlines too with notable projects or partnerships such as an exclusive agreement with COVAXX in 2020 for the global development and commercialization of UB-612 – a vaccine for COVID-19 – expanding access to India and UNICEF.
A peek into their history reveals that Aurobindo Pharma was incorporated back in ’86 before going public six years later in ’92. Since then it has grown exponentially becoming a leading player within the industry.
They’re also committed to R&D with manufacturing facilities located in countries such as India, Brazil, Portugal and the US. They also have R&D facilities based in India and the US.
Aurobindo Pharma has been recognised for their commitment to sustainability and received numerous awards for their contributions to the pharmaceutical industry.
Finally, on top of all that they run several subsidiaries worldwide including Aurobindo Pharma USA. So there you have it – an overview of one of India’s top pharma companies: Aurobindo Pharma Limited.
6. Mankind Pharma Ltd
First on our list is Mankind Pharma Ltd, a key player in India’s pharmaceutical landscape. With its headquarters nestled in Okhla Industrial Estate, Phase-III, New Delhi, it’s become a household name across the country.
Mankind Pharma reported robust financial figures for fiscal year 2022. Their net sales income rose to INR 8,127.15 crores from INR 7,486.22 crores the previous year. However, their net profit after tax saw a dip of 9.9%, settling at INR 1,309.7 crores compared to the previous year’s INR 1,453 crores.
| Fiscal Year | Net Sales Income (INR Crore) | Net Profit After Tax (INR Crore) |
|---|---|---|
| 2021 | 7,486.22 | 1,453 |
| 2022 | 8,127.15 | 1,309 |
Behind these numbers is an impressive workforce of over 18 thousand employees who help deliver quality products and services every day.
Mankind Pharma boasts an extensive product portfolio that spans various therapeutic areas including anti-infectives and cardiovascular treatments to neuro/CNS medications and vitamins/minerals/nutrients supplements among others.
The company also has several differentiated brands under its umbrella that cater to consumer healthcare needs—everything from condoms and pregnancy detection kits to antacid powders and anti-acne preparations are offered by them.
Speaking of clients served by Mankind Pharma – they aren’t just limited within India’s borders! The company has made its mark on the global stage by exporting products to over 34 international markets which include North America, Africa, and Asia.
Partnering with IBM Services was one major milestone for Mankind Pharma, which helped them deploy a high-performance platform based on SAP S/4HANA. This move has accelerated their business analytics by 50x and brought new ways to boost efficiency.
A brief look at the company’s history reveals it was founded in 1986 by R.C. Juneja and Rajeev Juneja. Since then, the company has grown leaps and bounds to become one of India’s leading pharmaceutical companies.
Mankind Pharma claims a significant market share as well, being the fourth-largest pharmaceutical company in terms of domestic sales and third-largest in terms of volume.
Innovation drives this pharma giant forward with an R&D centre that houses over 600 scientists who constantly strive to deliver better products. Their R&D expenditure for nine months ended December 2022 accounted for2.09%of revenue.
7. Torrent Pharmaceuticals Ltd
Situated in Ahmedabad, Gujarat, Torrent Pharmaceuticals Ltd is one of the leading players in the Indian pharma market. The company’s sustained growth and expansion into various therapeutic segments have made it a name to reckon with.
In the fiscal year 2022-23, this pharmaceutical giant reported impressive financials. Their annual revenue surpassed Rs 8,500 crores while their group revenue crossed Rs 20,000 crores. They managed to pull off a net profit of Rs 287 crores in the fourth quarter of that fiscal year alone.
As we plunge into the workforce data, as of 2020, there were over 12,881 employees working at Torrent Pharmaceuticals. This figure serves as a testament to not only its size but also its ability to create jobs.
Torrent Pharmaceuticals has carved out a niche for itself by operating in more than 40 countries around the globe with over:
- 2000 product registrations
- Active presence in therapeutic areas such as Cardiovascular (CV), Central Nervous System (CNS), gastro-intestinal
- Focus on diabetology, anti-infective and pain management segments
It’s noteworthy that they’ve ventured into nephrology and oncology recently while strengthening their focus on gynecology and pediatric segments.
Their clientele extends across more than forty nations including healthcare providers and patients alike. India, Brazil, Germany.
The nerve centre of all operations – Torrent House – is located at Off Ashram Road in Ahmedabad city of Gujarat state in India.
Back in 2019, Torrent Pharmaceuticals witnessed an impressive rise of about 32.51 percent in their consolidated net profit primarily due to strong sales recorded from most geographies. What’s even more interesting is they hold the number one position among Indian companies for having the largest market share in Brazil and Germany.
The company’s notable collaborations include a licensing agreement with Glenmark in 2019 for co-marketing of Remogliflozin Etabonate in India. Fast forward to 2022, Torrent Pharma made significant moves by acquiring four brands from Dr. Reddy’s Laboratories Ltd and entering into a licensing agreement with Medicine Patent Pool to manufacture and commercialise Pfizer’s oral COVID-19 treatment.
Founded by U.N Mehta back in 1959, Torrent Pharmaceuticals has come a long way from its initial days as Trinity Laboratories Ltd. Today, it operates across more than forty countries worldwide.
Their market dominance isn’t just limited to India. They’re ranked first amongst Indian Companies for holding the largest market share in both Brazil and Germany.
Innovation drives growth at Torrent Pharmaceuticals. Their focus on research & development is backed by state-of-the-art manufacturing facilities and an avant-garde R&D Center.
Their relentless efforts have earned them accolades including a remarkable rise of about 32.51 percent in their consolidated net profit back in 2019 due to robust sales recorded across most geographies.
Torrent Pharmaceuticals’ sphere of influence extends through seven fully owned subsidiaries spread across various countries:
- Heumann Pharma GmbH & Co Generica KG (Germany)
- Torrent Pharma GmbH (Germany)
- Torrent do Brasil Ltda (Brazil)
- ZAO Torrent Pharma (Russia)
- Torrent Pharma Inc (United States)
- Torrent Pharma Philippines Inc (Philippines)
- Torrent Pharma Canada Inc (Canada)
And let’s not forget their key acquisitions like “Styptovit-E”, “Finast”, “Finast-T”, and “Dynapress” from Dr. Reddy’s Laboratories Ltd.
The key driving forces behind the company’s success are Sudhir Mehta and Samir Mehta. Their leadership has played a significant role in shaping Torrent Pharmaceuticals into the industry leader it is today.
8. Zydus Lifesciences Ltd
Zydus Lifesciences is a powerhouse in the pharmaceutical industry, delivering impressive results quarter after quarter. Let’s delve into their performance. In the first quarter of 2023, they reported a net profit of Rs 1,087 crores – that’s double what they made the previous year. Their revenue also saw an impressive jump by 30% during this period. There was significant growth in their US business which grew by 57% year-on-year and contributed Rs 2,454 crores.
As of 2022, it employed approximately 23,000 individuals who are instrumental to its success.
Their product portfolio is diverse and extensive ranging from pharmaceuticals and diagnostics to herbal products and skincare items. Some key products you might recognise include Zydalis, Iladac L, Redclox D amongst others.
With clientele spread across hospitals, clinics and pharmacies around the world including markets like the US, Europe and Japan among others; Zydus has certainly established itself as a global player.
No wonder then that they’re headquartered at Ahmedabad in Gujarat India – a city known for being an entrepreneurial hub.
They’ve had some notable achievements over the years too. They ranked quite high on Fortune India’s top companies list in 2020 (100th place). And let’s not forget when their drug Desidustat received approval by the USFDA to initiate clinical trials on cancer patients.
Zydus have been involved in significant projects such as concluding a voluntary license agreement with Gilead back in 2015 which allowed them to make generics for hepatitis C treatment under brand name SoviHep.
Founded way back in 1952 by Ramanbhai Patel and Indravadan Modi, the company underwent a split in 1995 with the Patel family retaining Cadila Healthcare as their holding company. It later went public in 2000 and in 2022 was renamed Zydus Lifesciences Ltd.
Zydus is also committed to research and development. They work extensively across the spectrum to provide innovative products from New Molecular Entities (NMEs) to biologics, vaccines and new technologies for therapies.
In fact, just recently they ranked 100th on Fortune India’s top companies list again!
The company has several subsidiaries including Zydus Wellness which it owns over half of (57.59%). And its growth hasn’t been limited to organic means – they’ve made some key acquisitions too such as Química e Farmacêutica Nikkho do Brasil Ltda (Nikkho) under Zydus Healthcare Brasil Ltda back in 2007.
Key people at Zydus include Pankaj R. Patel who serves as Chairman and Sharvil P. Patel who is the Managing Director – individuals whose leadership has been instrumental to the success of this pharmaceutical giant.
9. Biocon Ltd
Diving into the specifics of Biocon Ltd, it’s clear that this company is a heavyweight in the pharma industry. In the fiscal year 2023, they reported an impressive revenue of Rs 11,550 Crore. That’s a whopping 38% increase from their previous year! Alongside this robust growth in revenue, their net profit also rose by 9%, hitting Rs 787 Crore before exceptional items.
Employing over 15,000 individuals as of 2023, Biocon Ltd takes pride in its diverse workforce. Their main offerings span active pharmaceutical ingredients (APIs), branded formulations, complex biologics and biosimilars. Their focus is on creating high quality life-saving biotherapeutics tailored to various medical needs worldwide.
Biocon isn’t limited to manufacturing alone; it extends its expertise through contract services which include drug licensing and research development for biotechnology and pharmaceutical companies globally. The nerve centre of Biocon lies at Electronic City in Bengaluru, India.
A glance at their track record reveals some noteworthy achievements too. In fact, they were ranked as the eighth ‘Global Top Employer’ by U.S Science Magazine in 2022 – marking their tenth consecutive appearance on this esteemed list!
September 2023 saw Biocon Biologics – a subsidiary of Biocon Ltd – finalising the integration of a newly acquired biosimilars business from Viatris in North America.
Tracing back its history to when it was publicly listed back in 2004, there’s no doubt that Biocon has made leaps and bounds within the biopharmaceutical sector with an unwavering commitment towards innovative solutions for chronic conditions.
The company’s global presence, extends to over 120 countries. Biocon continuously invests in research and development, with Rs 337 Crore dedicated to R&D investments in just the third quarter of fiscal year 2023.
The company was included in the S&P Global Sustainability Yearbook 2023 and recognised as an ‘industry mover’.
Subsidiaries play a key role in Biocon’s operations too. Its subsidiary, Biocon Biologics Ltd, successfully acquired the global biosimilars business from Viatris in North America during 2023.
At its helm are notable figures like Kiran Mazumdar-Shaw who serves as Executive Chairperson for both Biocon & Biocon Biologics, and Siddharth Mittal who is the Managing Director and Chief Executive Officer of the company.
To explore the traditional side of Indian healthcare, check out the leading ayurvedic companies in India.
10. Lupin Ltd.
Boasting a total revenue of ₹11,350.09 crores in the fiscal year 2022, Lupin Ltd has established itself as a key player in India’s pharma market. The company’s profit after tax for the same period was nothing short of impressive – ₹425.21 crores.
Proudly employing a workforce of over 24,204 individuals by 2023, this powerhouse is involved in a wide array of pharmaceutical ventures. From branded and generic formulations to biotechnology products and APIs, there’s no dearth to what they offer. Their key therapeutic areas include paediatrics, cardiovascular diseases, anti-infectives, diabetology and asthma treatments among others. But their crowning glory lies in being globally recognised as leaders in the Anti-Tuberculosis segment.
The reach of Lupin Ltd isn’t limited to just India – they’ve successfully penetrated over 100 markets worldwide including the U.S., South Africa and countries across Asia Pacific, Latin America, Europe and Middle East regions.
From its headquarters nestled in Mumbai since its inception by Desh Bandhu Gupta back in 1968, Lupin has grown exponentially over the years. Today it operates out of more than 100 countries with an all-encompassing portfolio featuring over 1,000 products!
Lupin is also one of the largest generic pharmaceutical companies based on global revenue share! In fact, within the U.S., most (over 70%) of their product offerings rank amongst top three contenders within respective segments.
Innovation is central at Lupin – proven by an investment amounting to nearly 8.7% of their FY22 revenue into research & development initiatives.
It comes as no surprise that recognitions have followed suit with Lupin consistently hailed as a ‘Great Place to Work’ within Biotechnology & Pharmaceuticals sectors.
On strategic fronts, Lupin’s acquisition of Gavis Pharmaceuticals and Novel Laboratories in July 2015 for a whopping $880 million is noteworthy.
At the helm of this successful venture are key individuals such as Vinita D. Gupta (CEO), Nilesh Gupta (MD) and Manju Deshbandhu Gupta (Chairman of the Board of Directors).
Conclusion on Pharma Companies in India
It’s clear that the pharmaceutical industry in India is not only booming, but also playing a pivotal role in the global healthcare domain. With its impressive growth trajectory and significant contributions to worldwide drug supply, these top 10 pharma companies have made their mark and continue to push boundaries.
You’ve seen how each one has its unique strengths, be it R&D prowess, manufacturing capabilities or innovative product portfolio. They’ve all shown resilience amidst challenges and displayed unwavering commitment towards improving health outcomes.
We hope this rundown of India’s top pharma companies has provided you with insightful information about their influence at home and abroad.
As you move forward, keep these names in mind. You never know when you’ll come across them — maybe when investing in stocks or perhaps when hearing about breakthroughs in medical science. These powerhouse entities certainly underline the fact that Indian pharma isn’t just surviving; it’s thriving!
While focusing on pharma, it’s also crucial to consider other sectors like education. Learn about the top education companies in India.
